0 Members and 1 Guest are viewing this topic.
Quote from: hamdani yusuf on 19/04/2024 12:42:40Just let them use alternative energy sourcessources, or simply move elsewhere.Circular argument - we were discussing the use of solar panels as construction materials.
Just let them use alternative energy sourcessources, or simply move elsewhere.
Evolution requires at least 3 ingredients: random change, replication (i.e. non-random change), and natural selection. It directs the path to the existence of particular structures of matter in the future.More conscious entities depend on more non-random changes, and depend on less random changes.
There are places where woods or clay are abundant, and practically available for free.
0:00 Complexity of life 0:40 Symbiosis and organelles2:35 Another organelle from more recent times 3:30 Endosymbiotic theory 4:00 Nitrogen and plants 5:15 New organelle that fixes nitrogen 5:50 Strange organism that possesses this 8:00 Confirmations 8:40 Important organism overall 9:20 Using this for plants?
0:00 Viruses and our relationship to them 1:25 Early virus interaction and infections 3:00 Myelin and its viral origins 4:00 How it makes us big 5:10 Why it made us better 6:20 How other animals evolved a different solution 7:10 Multiple infections over time 7:45 Mammalian features that were formed by a virus 9:00 All of this starts really early 10:00 Prevents immune system to help us survive11:00 Fetal development and viruses resembling HIV 12:10 Conclusions
There are several clinical trials and research initiatives in Japan focused on drugs and therapies aimed at rejuvenating mitochondria. One notable example is the approval of Imeglimin, a first-in-class mitochondria-targeted reagent for type 2 diabetes, by a French biopharmaceutical company, Poxel SA. This drug has been approved for marketing in Japan as of 2021 and has shown favorable safety and tolerability[2]. Imeglimin targets mitochondrial function, which is crucial for its therapeutic effects in diabetes management, indirectly contributing to mitochondrial health.Additionally, Japan is involved in various other clinical trials and research projects that explore mitochondrial rejuvenation through different mechanisms and diseases. For instance, the clinical trial registry and research initiatives often include studies on mitochondrial diseases and therapies that could potentially rejuvenate mitochondrial function. However, specific ongoing trials directly targeting mitochondrial rejuvenation in Japan were not detailed in the provided search results.For a comprehensive understanding of all current mitochondrial rejuvenation drug trials in Japan, one would typically refer to databases like ClinicalTrials.gov or research publications from relevant Japanese research institutions and pharmaceutical companies. These sources would provide detailed information on the scope, stage, and findings of such trials.